![Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma - Khashab - 2019 - British Journal of Haematology - Wiley Online Library Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma - Khashab - 2019 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/e90cee05-31c1-4c5a-8b4c-2db9e6caeb21/bjh15814-fig-0001-m.jpg)
Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma - Khashab - 2019 - British Journal of Haematology - Wiley Online Library
![Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management. - Abstract - Europe PMC Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management. - Abstract - Europe PMC](https://europepmc.org/articles/PMC3755934/bin/onc00813-1379-t01.jpg)
Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management. - Abstract - Europe PMC
![How I manage patients with follicular lymphoma - Casulo - 2019 - British Journal of Haematology - Wiley Online Library How I manage patients with follicular lymphoma - Casulo - 2019 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/df0aafa9-6a24-413b-8bda-b944ac5b7e78/bjh.v186.4.cover.jpg)
How I manage patients with follicular lymphoma - Casulo - 2019 - British Journal of Haematology - Wiley Online Library
![A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma - Cohen - 2015 - British Journal of Haematology - Wiley Online Library A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma - Cohen - 2015 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/748b56ba-a1ad-4d61-a1b0-d3c53629a4dd/bjh13637-fig-0001-m.jpg)
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma - Cohen - 2015 - British Journal of Haematology - Wiley Online Library
![M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy - Lockmer - 2020 - British Journal of Haematology - Wiley Online Library M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy - Lockmer - 2020 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/758bf6ec-2e45-4986-b49c-d5af5bdbade9/bjh16159-fig-0002-m.jpg)
M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy - Lockmer - 2020 - British Journal of Haematology - Wiley Online Library
![Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | SpringerLink Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-020-04021-6/MediaObjects/277_2020_4021_Fig4_HTML.png)
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | SpringerLink
![Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study - The Lancet Haematology Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study - The Lancet Haematology](https://www.thelancet.com/cms/attachment/c880e7d6-3884-4edd-a1bc-b882d7c24b3c/gr2_lrg.jpg)
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study - The Lancet Haematology
![The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival - Bishton - The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival - Bishton -](https://onlinelibrary.wiley.com/cms/asset/c2e18953-562a-4aef-b0a1-39bb5057af32/bjh16555-fig-0001-m.jpg)
The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival - Bishton -
![Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy | SpringerLink Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-016-2690-2/MediaObjects/277_2016_2690_Fig1_HTML.gif)
Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy | SpringerLink
![Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma | SpringerLink Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-022-05037-w/MediaObjects/277_2022_5037_Fig1_HTML.png)
Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma | SpringerLink
![High ten‐year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R‐FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study - Nastoupil - 2017 - British Journal of Haematology - High ten‐year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R‐FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study - Nastoupil - 2017 - British Journal of Haematology -](https://onlinelibrary.wiley.com/cms/asset/54f541ba-357c-49a2-afcb-e875eebd9510/bjh.2017.177.issue-2.cover.jpg)
High ten‐year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R‐FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study - Nastoupil - 2017 - British Journal of Haematology -
![Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | SpringerLink Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-020-04021-6/MediaObjects/277_2020_4021_Fig2_HTML.png)
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | SpringerLink
![Functional plasticity and recurrent cell states of malignant B cells in follicular lymphoma | bioRxiv Functional plasticity and recurrent cell states of malignant B cells in follicular lymphoma | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2022/04/08/2022.04.06.487285/F7.large.jpg)
Functional plasticity and recurrent cell states of malignant B cells in follicular lymphoma | bioRxiv
![Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial - The Lancet Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial - The Lancet](https://www.thelancet.com/cms/attachment/2094227228/2077090889/gr1.gif)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial - The Lancet
![Functional plasticity and recurrent cell states of malignant B cells in follicular lymphoma | bioRxiv Functional plasticity and recurrent cell states of malignant B cells in follicular lymphoma | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2022/04/08/2022.04.06.487285/F1.large.jpg)
Functional plasticity and recurrent cell states of malignant B cells in follicular lymphoma | bioRxiv
![The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival - Bishton - The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival - Bishton -](https://onlinelibrary.wiley.com/cms/asset/4dc2614f-2257-4219-bb2f-62ae184912ae/bjh16555-fig-0003-m.jpg)